1.32
-1.49%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About VIVA Biotech Holdings
Its shares trade on HKEX under the ticker 1873.HK. It has been listed since 9 May 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.02bn and net income of CN¥256.3m. At that date it held total assets of CN¥8.40bn and shareholders' equity of CN¥4.66bn.
Viva Biotech Holdings engages in preclinical research and development of innovative drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-05-09. The firm is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Company’s core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The firm operates its businesses mainly in the United States, China, Europe and other regions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 9 May 2019
- Employees
- 731
Leadership
Pay as last reported
- Mr. Chen Cheney MaoExecutive Chairman of the Board, Chief Executive Officer, since 2018CN¥2.4m
- Mr. Wei XiongChief Financial Officer
- Mr. Ying WuExecutive Vice President, Executive Director, since 2009CN¥2.7m
- Mr. Zhixiong YeChief Scientific Officer
- Mr. Delin RenExecutive Director, since 2018CN¥3.7m
- Ms. Hing Ling ChauJoint Company Secretary
- Ms. Xiaoyu FeiJoint Company Secretary
- Mr. Hui WangNon-Executive Director
- Mr. Yuting WuNon-Executive DirectorCN¥225,000
- Dr. Lei FuNon-Executive Independent DirectorCN¥225,000
- Ms. Xiangrong LiNon-Executive Independent DirectorCN¥225,000
- Mr. Haiguang WangNon-Executive Independent DirectorCN¥225,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 82
- Social
- 80
- Governance
- 66
- Direct emissions (scope 1)
- 1,466.05 t
- Energy emissions (scope 2)
- 45,285.23 t
- Women in the workforce
- 46%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- VIVA Biotech Holdings has a strong track record in the biotech industry, consistently delivering innovative solutions and high-quality services to its clients.
- The company boasts a state-of-the-art infrastructure and well-equipped laboratories, enabling efficient and timely execution of projects.
- VIVA Biotech Holdings has a highly skilled and experienced team of scientists and researchers who have expertise in various disciplines, enhancing the company's overall capabilities.
Weaknesses
- One of the weaknesses of VIVA Biotech Holdings is its heavy dependence on a few key clients for a significant portion of its revenue, which exposes the company to potential financial risks if there are any disruptions in those client relationships.
- The rapid pace of technological advancements in the biotech industry poses a challenge for VIVA Biotech Holdings to consistently stay up-to-date and invest in the latest equipment and technologies.
- The company may face challenges in retaining top talent and attracting new skilled professionals, due to the competitive nature of the biotech market.
Opportunities
- The biotech industry is experiencing significant growth worldwide, driven by increased demand for personalized medicine and advancements in genetic research. This presents VIVA Biotech Holdings with ample opportunities to expand its client base and explore new markets.
- VIVA Biotech Holdings can capitalize on the rising trend of outsourcing in the biotech sector, as more companies look to partner with specialized service providers to reduce costs and enhance efficiency.
- The company can leverage its strong reputation and expertise to forge strategic partnerships and collaborations with leading pharmaceutical companies and academic institutions, opening doors for joint research projects and mutually beneficial ventures.
Threats
- Intense competition within the biotech industry poses a threat to VIVA Biotech Holdings, as new entrants and established competitors vie for market share and clients.
- Legal and regulatory uncertainties in the biotech sector can impact the operations and growth prospects of VIVA Biotech Holdings, requiring the company to stay vigilant and adapt to changing compliance requirements.
- Emerging technologies or breakthrough inventions in the biotech field could disrupt the existing business models and services offered by VIVA Biotech Holdings, necessitating constant innovation and adaptation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.